Taysha Gene Therapies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 04:08 pm EST
Share
Taysha Gene Therapies, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 4.75 million. Net loss was USD 117.09 million compared to USD 26.53 million a year ago. Basic loss per share from continuing operations was USD 0.93 compared to USD 0.65 a year ago. Diluted loss per share from continuing operations was USD 0.93 compared to USD 0.65 a year ago.
For the nine months, sales was USD 11.85 million. Net loss was USD 159.31 million compared to USD 110.94 million a year ago. Basic loss per share from continuing operations was USD 1.88 compared to USD 2.79 a year ago. Diluted loss per share from continuing operations was USD 1.88 compared to USD 2.79 a year ago.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Companyâs lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). It received orphan drug designation from the European Commission for TSHA-120 for the treatment of GAN.